Superworth

BridgeBio Pharma price to book ratio BBIO

Market value divided by the book value of the company's net assets, since 2019.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
144×
Apr 2021
Peer median
7.7×

BridgeBio Pharma's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Apr 2021, at 144×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2021144×42.5×182×
202053.2×6.7×53.2×
20199.9×7.3×11.2×

Against its peers

Companies in Drug Manufacturers - General nearest BridgeBio Pharma's size, closest first, today.

CompanyPrice to book ratio
BBIOBridgeBio Pharman/m
JAZZJazz Pharmaceuticals2.9×
BMRNBiomarin Pharmaceutical1.7×
CORTCorcept Therapeutics13.2×
PTGXProtagonist Therapeutics10.6×
TGTXTG Therapeutics13.7×
ALKSAlkermes plc.4.0×
AMRXAmneal Pharmaceuticals197×
LGNDLigand Pharmaceuticals6.3×
KNSAKiniksa Pharmaceuticals International9.2×
BIIBBiogen2.0×
Peer median7.7×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on BridgeBio Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.